Yamazaki, Takahiro
Galluzzi, Lorenzo
Article History
Received: 21 February 2022
Revised: 14 March 2022
Accepted: 14 March 2022
First Online: 26 March 2022
Competing interests
: LG has been holding research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Phosplatin, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts to declare.